---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-029514"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:16:14.694143+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon launches public offering, private placement; reports $125.2M cash, Novo milestone, clinical timelines

## Summary
- Underwritten public offering of common stock launched; Jefferies and Piper Sandler joint book-running managers.
- Concurrent private placement to Invus affiliate via preemptive right; option to purchase additional shares pro rata.
- Preliminary cash position $125.2M (unaudited) as of year-end 2025; $10M milestone received from Novo Nordisk in Jan 2026.
- SONATA-HCM (sotagliflozin) Phase 3 enrollment completion expected mid-2026; topline data Q1 2027.
- NDA resubmission for ZYNQUISTA in type 1 diabetes potentially in 2026, supported by STENO1 safety data.

## SEC filing metadata
- accession: 0001193125-26-029514
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000119312526029514/0001193125-26-029514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000119312526029514/d61153d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-029514
- JSON: https://secwatch.observer/filing/0001193125-26-029514.json
- Plain text: https://secwatch.observer/filing/0001193125-26-029514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.